MSD’s Keytruda bags another trial success in NSCLC

MSD’s Keytruda has significantly increased overall survival in patients with lung cancer expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope.Original Article